ECSS
AUPH icon

Eurizon Capital SGR SpA’s Aurinia Pharmaceuticals AUPH Stock Holding History

Eurizon Capital SGR SpA’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$227K Sell
13,370
-5,734
-30% -$91.6K ﹤0.01% 724
2026
Q1 		$283K Hold
19,104
– – ﹤0.01% 704
2025
Q4 		$305K Buy
+19,104
New +$271K ﹤0.01% 611

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eurizon Capital SGR SpA's AUPH Position: Q2 2026 in Review

Eurizon Capital SGR SpA reduced its Aurinia Pharmaceuticals (AUPH) stake by 30% in Q2 2026, selling an estimated $91.6K and leaving 13,370 shares worth $227K. The position accounts for ﹤0.01% of the portfolio, ranked #724.

Eurizon Capital SGR SpA first reported a position in AUPH in Q4 2025 and has held it in 3 quarters since. The position peaked at $305K in Q4 2025. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Eurizon Capital SGR SpA held 13,370 shares of Aurinia Pharmaceuticals worth $227K as of Q2 2026.
  • Eurizon Capital SGR SpA sold 5,734 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $91.6K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #724 holding.
  • Eurizon Capital SGR SpA first reported a position in Aurinia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Eurizon Capital SGR SpA's Aurinia Pharmaceuticals position peaked at $305K in Q4 2025.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.